Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Invesco Solar ETF (TAN) Price & Performance

Merck & Co., Inc.Trade
Invesco Solar ETFTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Invesco Solar ETF — how do they compare? Merck & Co., Inc. trades at $130.38 (market cap $323.00B), while Invesco Solar ETF trades at $52.8. The key difference: Merck & Co., Inc. pays a 2.6% dividend while Invesco Solar ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.

MRKTAN
Market Cap
$323.00B
Sector
HealthSector/Thematic
52-Week High
$131.84$73.95
52-Week Low
$77.60$36.62
Enterprise Value
$369.77B
Dividend Yield
2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.

The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.

Invesco Solar ETF

TAN trades at $52.75, up 2.93% today amid positive solar sector news. Technical indicators are bearish overall, with moving averages signaling caution and RSI-6 suggesting overbought conditions. Recent tariffs on imported solar products have boosted sentiment, but the ETF faces headwinds from high volatility and regulatory uncertainty.

The outlook is mixed: supportive policies may drive growth, yet valuation concerns and interest rate sensitivity pose risks. Investors should weigh exposure to utility-scale solar growth against sector volatility and top-heavy holdings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Invesco Solar ETF

TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.

Read more on TAN